UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/592,929	09/15/2006	Tomas Drmota	1133651-0003	2827
7470 WHITE & CAS	7590 03/08/201 SE LLP	0	EXAMINER	
PATENT DEPA			LI, RUIXIANG	
1155 AVENUE OF THE AMERICAS NEW YORK, NY 10036			ART UNIT	PAPER NUMBER
			1646	
			MAIL DATE	DELIVERY MODE
			03/08/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
Office Action Occurrence	10/592,929	DRMOTA ET AL.			
Office Action Summary	Examiner	Art Unit			
	RUIXIANG LI	1646			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence ad	ldress		
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	J. lely filed the mailing date of this o ○ (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on					
	- action is non-final.				
3) Since this application is in condition for allowan					
closed in accordance with the practice under E.	x parte Quayle, 1935 C.D. 11, 45	3 O.G. 213.			
Disposition of Claims					
4) Claim(s) <u>1-16</u> is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) <u>1-16</u> are subject to restriction and/or e					
Application Papers					
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the construction represents the specific	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CF	, ,		
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prioric application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No ed in this National	Stage		
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ite			

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which

are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this

action, to elect a single invention to which the claims must be restricted.

I. Claims 1-8, drawn to an isolated polynucleotide molecule comprising a nucleic acid

sequence encoding a bNK1r polypeptide.

II. Claims 9-11, an isolated gNK1r polypeptide.

III. Claims 12-14, drawn to a method for identifying a chemical compound capable of

modulating the activity of gNK1r.

IV. Claim 15 and 16, drawn to a pharmaceutical composition comprising a gNK1r

modulator and a method of making such a composition.

2. The groups of inventions listed above do not relate to a single general inventive

concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or

corresponding special technical features for the following reasons:

Invention Groups I-IV lack unity of invention because even though the

inventions of these groups require the technical feature of an isolated polynucleotide

encoding a gNK1r polypeptide. This technical feature is not a special technical

feature as it does not make a contribution over the prior art in view of Stout et al.

(*Annu. Rev. Pharmacol. Toxicol.* 41:877-906, 2001). Stout et al. teach a gerbil NK1r polypeptide (page 892, Table 1). Therefore, the shared technical feature does not make a contribution over the prior art

Accordingly, Groups I-IV are not so linked by the same or a corresponding special technical feature as to form a single general inventive concept. Thus, unity of invention is lacking and restriction is appropriate.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48 (b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48 (b) and by the fee required under 37 CFR 1.17 (l).

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ruixiang Li whose telephone number is (571) 272-0875. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol, can be reached on (571) 272-0835. The fax number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published

Application/Control Number: 10/592,929 Page 4

Art Unit: 1646

applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, please contact the Electronic Business Center (EBC) at the toll-free phone number 866-217-9197.

/Ruixiang Li/ Primary Examiner, Art Unit 1646

Ruixiang Li, Ph.D. March 3, 2010